Clinical Trial Update: Study of Frontline Dasatinib Plus Chemotherapy in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (PH+ALL) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update on frontline dasatinib plus chemotherapy in Philadelphia chromosome–positive acute lymphoblastic leukemia (PH+ALL) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Philadelphia-positive Acute Lymphoblastic Leukemia

Drugs mentioned

• DASATINIB (Dasatinib)

Snippet

Sponsor: Goethe University | Conditions: Philadelphia Positive Acute Lymphoblastic Leukemia | Phase 2 | Status: COMPLETED